Corrigendum to: “Comparison of angiotensin-(1–7), losartan and their combination on atherosclerotic plaque formation in apolipoprotein E knockout mice” [Atherosclerosis 240(2) (2015) 544–549] (Atherosclerosis (2015) 240(2) (544–549), (S002191501500146X), (10.1016/j.atherosclerosis.2015.02.055));Comparison of angiotensin-(1-7), losartan and their combination on atherosclerotic plaque formation in apolipoprotein E knockout mice

Atherosclerosis

Volumn 240, Issue 2, 2015, Pages 544-549

  Yang, Jianmin ^a   Sun, Yu ^b   Dong, Mei ^a   Yang, Xiaoyan ^a   Meng, Xiao ^a   Niu, Rongrong ^b   Guan, Juan ^b   Zhang, Yun ^a   Zhang, Cheng ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Angiotensin II type 1 receptor blocker; Angiotensin (1 7); Atherosclerosis

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN[1-7]; APOLIPOPROTEIN E; LOSARTAN; MAS RECEPTOR; SUPEROXIDE; UNCLASSIFIED DRUG; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN I; ANGIOTENSIN I (1-7); LIPID; PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; ENDOTHELIUM; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LIPID BLOOD LEVEL; LIPID DIET; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; ABDOMINAL AORTA; ANIMAL; AORTIC DISEASES; ATHEROSCLEROSIS; BLOOD; BLOOD PRESSURE; CELL LINE; CELL MOTION; COMBINATION DRUG THERAPY; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; MACROPHAGE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TIME FACTOR; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANGIOTENSIN I; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA, ABDOMINAL; AORTIC DISEASES; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD PRESSURE; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; HUMANS; LIPIDS; LOSARTAN; MACROPHAGES; MALE; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; PEPTIDE FRAGMENTS; PLAQUE, ATHEROSCLEROTIC; RENIN-ANGIOTENSIN SYSTEM; SUPEROXIDES; TIME FACTORS; VASODILATION;

EID: 84929660400     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2022.01.019     Document Type: Erratum

References (32)

1. Duprez D.A. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J.Hypertens. 2006, 24:983-991.
2. Lu H., Balakrishnan A., Howatt D.A., Wu C., Charnigo R., Liau G., Cassis L.A., Daugherty A. Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis. Br. J. Pharmacol. 2012, 165:2000-2008.
3. Blessing E., Preusch M., Kranzhofer R., Kinscherf R., Marx N., Rosenfeld M.E., Isermann B., Weber C.M., Kreuzer J., Grafe J., Katus H.A., Bea F. Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice. Atherosclerosis 2008, 199:295-303.
4. Jiang F., Yang J., Zhang Y., Dong M., Wang S., Zhang Q., Liu F.F., Zhang K., Zhang C. Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets. Nat. Rev. Cardiol. 2014, 11:413-426.
5. Yang J.M., Dong M., Meng X., Zhao Y.X., Yang X.Y., Liu X.L., Hao P.P., Li J.J., Wang X.P., Zhang K., Gao F., Zhao X.Q., Zhang M.X., Zhang Y., Zhang C. Angiotensin-(1-7) dose-dependently inhibits atherosclerotic lesion formation and enhances plaque stability by targeting vascular cells. Arterioscler. Thromb. Vasc. Biol. 2013, 33:1978-1985.
6. McKinney C.A., Fattah C., Loughrey C.M., Milligan G., Nicklin S.A. Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodelling. Clin. Sci. (London) 2014, 126:815-827.
7. Bomback A.S., Toto R. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination. Am. J. Hypertens. 2009, 22:1032-1040.
8. Xu C., Ding W., Zhang M., Gu Y. Protective effects of angiotensin-(1-7) administrated with an angiotensin-receptor blocker in a rat model of chronic kidney disease. Nephrol. (Carlton) 2013, 18:761-769.
9. Tesanovic S., Vinh A., Gaspari T.A., Casley D., Widdop R.E. Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1606-1613.
10. Lovren F., Pan Y., Quan A., Teoh H., Wang G., Shukla P.C., Levitt K.S., Oudit G.Y., Al-Omran M., Stewart D.J., Slutsky A.S., Peterson M.D., Backx P.H., Penninger J.M., Verma S. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H1377-H1384.
11. Petersen E.J., Miyoshi T., Yuan Z., Hirohata S., Li J.Z., Shi W., Angle J.F. siRNA silencing reveals role of vascular cell adhesion molecule-1 in vascular smooth muscle cell migration. Atherosclerosis 2008, 198:301-306.
12. Zhang F., Hu Y., Xu Q., Ye S. Different effects of angiotensin II and angiotensin-(1-7) on vascular smooth muscle cell proliferation and migration. PLoS One 2010, 5. e12323.
13. Lee S.J., Choi E.K., Seo K.W., Bae J.U., Park S.Y., Kim C.D. TLR4-mediated expression of Mac-1 in monocytes plays a pivotal role in monocyte adhesion to vascular endothelium. PLoS One 2014, 9. e104588.
14. Pfeffer M.A., McMurray J.J., Velazquez E.J., Rouleau J.L., Kober L., Maggioni A.P., Solomon S.D., Swedberg K., Van de Werf F., White H., Leimberger J.D., Henis M., Edwards S., Zelenkofske S., Sellers M.A., Califf R.M. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N.Engl. J. Med. 2003, 349:1893-1906.
15. Yano H., Hibi K., Nozawa N., Ozaki H., Kusama I., Ebina T., Kosuge M., Tsukahara K., Okuda J., Morita S., Umemura S., Kimura K. Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor. Circ. J. 2012, 76:1442-1451.
16. Yusuf S., Teo K.K., Pogue J., Dyal L., Copland I., Schumacher H., Dagenais G., Sleight P., Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N.Engl. J. Med. 2008, 358:1547-1559.
17. van Diepen J.A., Berbee J.F., Havekes L.M., Rensen P.C. Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis. Atherosclerosis 2013, 228:306-315.
18. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
19. Gutierrez E., Flammer A.J., Lerman L.O., Elizaga J., Lerman A., Fernandez-Aviles F. Endothelial dysfunction over the course of coronary artery disease. Eur. Heart J. 2013, 34:3175-3181.
20. Prasad A., Tupas-Habib T., Schenke W.H., Mincemoyer R., Panza J.A., Waclawin M.A., Ellahham S., Quyyumi A.A. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000, 101:2349-2354.
21. Tallant E.A., Clark M.A. Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension 2003, 42(4):574-579.
22. Strawn W.B., Ferrario C.M., Tallant E.A. Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 1999, 33(1 Pt 2):207-211.
23. Walters P.E., Gaspari T.A., Widdop R.E. Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension 2005, 45:960-966.
24. Bosnyak S., Jones E.S., Christopoulos A., Aguilar M.I., Thomas W.G., Widdop R.E. Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin. Sci. (London) 2011, 121:297-303.
25. Ferrario C.M., Varagic J. The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function. Am. J. Physiol. Ren. Physiol. 2010, 298:F1297-F1305.
26. Shi Y., Lo C.S., Padda R., Abdo S., Chenier I., Filep J.G., Ingelfinger J.R., Zhang S.L., Chan J.S. Ang 1-7 prevents systemic hypertension, attenuates oxidative stress and tubulointerstitial fibrosis, and normalizes renal angiotensin-converting enzyme 2 and mas receptor expression in diabetic mice. Clin. Sci. (London) 2015, 128:649-663.
27. Iwai M., Chen R., Li Z., Shiuchi T., Suzuki J., Ide A., Tsuda M., Okumura M., Min L.J., Mogi M., Horiuchi M. Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice. Circulation 2005, 112:1636-1643.
28. Jawien J., Toton-Zuranska J., Gajda M., Niepsuj A., Gebska A., Kus K., Suski M., Pyka-Fosciak G., Nowak B., Guzik T.J., Marcinkiewicz J., Olszanecki R., Korbut R. Angiotensin-(1-7) receptor Mas agonist ameliorates progress of atherosclerosis in apoE-knockout mice. J.Physiol. Pharmacol. 2012, 63:77-85.
29. Tesanovic S., Vinh A., Gaspari T.A., Casley D., Widdop R.E. Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1606-1613.
30. Ohshima K., Mogi M., Nakaoka H., Iwanami J., Min L.J., Kanno H., Tsukuda K., Chisaka T., Bai H.Y., Wang X.L., Ogimoto A., Higaki J., Horiuchi M. Possible role of angiotensin-converting enzyme 2 and activation of angiotensin II type 2 receptor by angiotensin-(1-7) in improvement of vascular remodeling by angiotensin II type 1 receptor blockade. Hypertension 2014, 63:e53-59.
31. Valente A.J., Yoshida T., Murthy S.N., Sakamuri S.S., Katsuyama M., Clark R.A., Delafontaine P., Chandrasekar B. Angiotensin II enhances AT1-Nox1 binding and stimulates arterial smooth muscle cell migration and proliferation through AT1, Nox1, and interleukin-18. Am. J. Physiol. Heart Circ. Physiol. 2012, 303:H282-H296.
32. Dong B., Yu Q.T., Dai H.Y., Gao Y.Y., Zhou Z.L., Zhang L., Jiang H., Gao F., Li S.Y., Zhang Y.H., Bian H.J., Liu C.X., Wang N., Xu H., Pan C.M., Song H.D., Zhang C., Zhang Y. Angiotensin-converting enzyme-2 overexpression improves left ventricular remodeling and function in a rat model of diabetic cardiomyopathy. J.Am. Coll. Cardiol. 2012, 59:739-747.